Co Diagnostics Valuation
| CODX Stock | USD 2.52 0.03 1.20% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Co Diagnostics owns a latest Real Value of $13.11 per share. The recent price of the firm is $2.52. Our model approximates the value of Co Diagnostics from analyzing the firm fundamentals such as Shares Owned By Insiders of 5.77 %, shares owned by institutions of 12.46 %, and Return On Asset of -0.38 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Co Diagnostics' valuation include:
Undervalued
Today
Please note that Co Diagnostics' price fluctuation is relatively risky at this time. Calculation of the real value of Co Diagnostics is based on 3 months time horizon. Increasing Co Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Co Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CODX Stock. However, Co Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.52 | Real 13.11 | Target 45.0 | Hype 1.53 | Naive 2.79 |
The intrinsic value of Co Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Co Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Co Diagnostics helps investors to forecast how CODX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Co Diagnostics more accurately as focusing exclusively on Co Diagnostics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Co Diagnostics' intrinsic value based on its ongoing forecasts of Co Diagnostics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Co Diagnostics' closest peers.
Co Diagnostics Cash |
|
Co Diagnostics Total Value Analysis
Co Diagnostics is currently forecasted to have valuation of (4.76 M) with market capitalization of 5.22 M, debt of 2.15 M, and cash on hands of 86.49 M. The negative valuation of Co Diagnostics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Co Diagnostics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(4.76 M) | 5.22 M | 2.15 M | 86.49 M |
Co Diagnostics Investor Information
The company has price-to-book (P/B) ratio of 0.13. Some equities with similar Price to Book (P/B) outperform the market in the long run. Co Diagnostics recorded a loss per share of 29.4. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 2nd of January 2026. Based on the key indicators related to Co Diagnostics' liquidity, profitability, solvency, and operating efficiency, Co Diagnostics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Co Diagnostics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Co Diagnostics has an asset utilization ratio of 6.12 percent. This suggests that the Company is making $0.0612 for each dollar of assets. An increasing asset utilization means that Co Diagnostics is more efficient with each dollar of assets it utilizes for everyday operations.Co Diagnostics Profitability Analysis
Based on Co Diagnostics' profitability indicators, Co Diagnostics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Co Diagnostics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2015-12-31 | Previous Quarter -7.7 M | Current Value -5.9 M | Quarterly Volatility 7.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.8 | 0.86 |
|
|
For Co Diagnostics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Co Diagnostics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Co Diagnostics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Co Diagnostics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Co Diagnostics over time as well as its relative position and ranking within its peers.
Co Diagnostics Earnings per Share Projection vs Actual
The next projected EPS of Co Diagnostics is estimated to be -3.75 with future projections ranging from a low of -3.9 to a high of -3.6. Co Diagnostics' most recent 12-month trailing earnings per share (EPS TTM) is at -29.4. Please be aware that the consensus of earnings estimates for Co Diagnostics is based on EPS before non-recurring items and includes expenses related to employee stock options.Co Diagnostics Earnings Estimation Breakdown
The calculation of Co Diagnostics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Co Diagnostics is estimated to be -3.75 with the future projection ranging from a low of -3.9 to a high of -3.6. Please be aware that this consensus of annual earnings estimates for Co Diagnostics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-3.9 Lowest | Expected EPS | -3.6 Highest |
Co Diagnostics Earnings Projection Consensus
Suppose the current estimates of Co Diagnostics' value are higher than the current market price of the Co Diagnostics stock. In this case, investors may conclude that Co Diagnostics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Co Diagnostics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 2 | 42.95% | 0.0 | -3.75 | -29.4 |
Co Diagnostics Ownership Allocation
Co Diagnostics owns 5.77 % of its outstanding shares held by insiders and 12.46 % owned by institutions.Co Diagnostics Profitability Analysis
The company reported the previous year's revenue of 3.92 M. Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 172.84 K.About Co Diagnostics Valuation
Our relative valuation model uses a comparative analysis of Co Diagnostics. We calculate exposure to Co Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Co Diagnostics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.4 M | 3.2 M | |
| Pretax Profit Margin | (8.64) | (9.07) | |
| Operating Profit Margin | (9.21) | (9.67) | |
| Net Loss | (8.65) | (9.08) | |
| Gross Profit Margin | 0.86 | 0.80 |
Co Diagnostics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1 M | |
| Quarterly Earnings Growth Y O Y | 0.308 | |
| Forward Price Earnings | 16 |
Co Diagnostics Current Valuation Indicators
Valuation refers to the process of determining the present value of Co Diagnostics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value CODX we look at many different elements of the entity such as CODX's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Co Diagnostics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Co Diagnostics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Co Diagnostics' worth.Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.